VK4-116 Phase I Study With Food-Effect
Key facts
- Who runs it
- National Institute on Drug Abuse (NIDA)
- Where
- Overland Park, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 25 Sept 2026
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 7 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VK4-116
- Placebo
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Be a healthy male or female volunteer between 18 and 60 years of age, inclusive, at the time of consent; The masculine / feminine gender is used without any discrimination and with the aim to lighten the text
- Have a body mass index (BMI) within a range of 17.0 to 36.0 kg/m2 and a minimum weight of at least 50.0 kg at screening
- Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures
- Have no clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG
- A female study participant must meet one of the following criteria:; If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:; abstinence from heterosexual intercourse, ii. hormonal contraceptives (e.g., injectable/implant/insertable hormonal birth control products, transdermal patch), iii. intrauterine device (with or without hormones). OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication; If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by follicle stimulating hormone (FSH) levels (≥40 mIU/mL); A male study participant that engages in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication
- Be able and willing to comply with protocol requirements and the rules and regulations of the study site, and be likely to complete all the study treatments
Who cannot take part
- Have donated blood (excluding plasma donation) of approximately 500 mL within 56 days prior to screening
- Have donated plasma within 7 days prior to screening
- Have undergone treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening
- Have taken prescribed medications within 14 days of Day -1 or over-the-counter medications, dietary supplements, herbal products, or vitamins within 7 days or 5 half-lives (if known), whichever is longer, of Day -1
- Have a positive urine drug test for alcohol, opioids (e.g., codeine, heroin, fentanyl, morphine, oxycodone, etc.), cocaine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), benzodiazepines, tetrahydrocannabinol (THC), barbiturates, propoxyphene, or phencyclidine/phenylcyclohexyl piperidine (PCP) at admission
- Have a history of consumption of any product containing grapefruit, pomelo, Seville oranges, or alcohol within 7 days before study drug dosing on Day 1
- Have consumed any product containing caffeine or xanthine within 24 hours before study drug dosing on Day 1
- Have a sitting systolic blood pressure (BP) >140 mmHg, diastolic BP >90 mmHg and heart rate (HR) <45 or >100 beats per minute (BPM) at screening and clinic intake
- History of unstable angina; a history of myocardial infarction; or a history of a clinically significant cardiac arrhythmia,
- Have a history of suicide attempts or current or recent evidence of suicidal ideation in the past 12 months based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Have a positive serology for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV)
- Have positive results for a coronavirus disease 2019 (COVID-19) test
- Have a history of anaphylaxis and known allergy to any drug formulation
- Have any clinically significant finding within one year of Screening on medical history, physical examination, complete neurological examination, clinical laboratory test, vital signs or ECGs that contraindicate participation in the study. This includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, gastrointestinal (GI), pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy
- Has a QT interval corrected for heart rate using Fredericia formula >450 milliseconds in males or >470 milliseconds in females, or evidence of left bundle branch blocks (Note: right bundle branch block is acceptable), second or third degree AV block, or evidence of left ventricular hypertrophy on ECG
- Have a history of liver disease or current elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), 2 × the upper limit of normal (ULN)
- Have a history of renal disease or current renal function test values as follows:; blood urea nitrogen (BUN) >2 × ULN,; creatinine (Cr) >1.5 mg/dL
- Have hemoglobin value of <13 g/dL for men and <12 g/dL for women
- Use nicotine products via smoking/vaping in past 6 months
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
This trial is currently available in United States.
- Altasciences Clinical KansasOverland Park, United StatesContact: Debra Kelsh, MDTaking people
About the trial
What the trial wants to find out
This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
The 7 groups in the trial
- 50 mg doseTreatment being tested
oral administration in fasted state
Treatment: VK4-116
- 100 mg doseTreatment being tested
oral administration in fasted state
Treatment: VK4-116
- 200 mg doseTreatment being tested
oral administration in fasted state
Treatment: VK4-116
- 400 mg doseTreatment being tested
oral administration in fasted state
Treatment: VK4-116
- 500 mg doseTreatment being tested
oral administration in fasted state
Treatment: VK4-116
- 200 mg dose in fed stateTreatment being tested
oral administration in fed state
Treatment: VK4-116
- placeboPlacebo, for comparison
oral administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study With Food-Effect Cohort to Assess the Safety, Tolerability, and Pharmacokinetics of Oral (R) VK4-116 in Healthy Volunteers
- Criteria questions
- Built from NCT06808932, who can take part
- Record updated
- 13 November 2026